One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1016/j.jns.2017.08.1036
Copy DOI
Export
Save
Share
Cite Journal: Journal of the Neurological Sciences |  Publication Date: Oct 1, 2017 |
Affiliation: Hokkaido University
Background: The adenosine A2A antagonist istradefylline has been used to treat Parkinson's disease (PD) with symptoms of wearing-off since 2013 in Japan. Previous randomized controlled trials (RCTs) of istradefylline compared with placebo included PD patients experiencing an average daily OFF time of > 2 hours.
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
